Clinical Trial Update: SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe [Phase 4]

View source ↗

Summary

A post-marketing Phase 4 study evaluating the XIENCE V Everolimus Eluting Coronary Stent System in Europe has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Restenosis

Drugs mentioned

• XIENCE V Everolimus Eluting Coronary Stent System (Everolimus-eluting coronary stent)

Snippet

Sponsor: Abbott Medical Devices | Conditions: Coronary Disease, Coronary Artery Disease | Phase 4 | Status: COMPLETED